Background: Acute kidney injury is common in critically ill patients. Fenoldopam mesylate is a potent dopamine A-1 receptor agonist that increases blood flow to the renal cortex and outer medulla. Because there is uncertainty about the benefits of fenoldopam in such a setting, we performed a systematic review of randomized controlled trials of intensive care unit patients or those undergoing major surgery.
A
cute kidney injury is a serious complication in critically ill patients and is associated with markedly increased morbidity and mortality. [1] [2] [3] [4] Numerous studies using parenteral vasodilators to prevent or treat acute kidney injury in postoperative patients or those with multiorgan dysfunction have given conflicting results. [5] [6] [7] Fenoldopam mesylate is a benzazepine derivative that is a potent short-acting dopamine A-1 receptor agonist that decreases systemic vascular resistance while simultaneously increasing renal blood flow. [8] [9] [10] In addition to its use in patients with hypertensive emergencies, 11 fenoldopam appears to improve renal function in patients with severe hypertension [12] [13] [14] and critically ill patients receiving positive end-expiratory pressure. 15 Animal model studies and clinical trials documented the ability of fenoldopam to augment blood flow to the kidneys and other organs. 16 In a recent clinical trial of patients with sepsis, fenoldopam improved perfusion of the gastric mucosa in patients with septic shock. 17 These clinically useful pharmacological properties have led to the widespread use of fenoldopam in the prevention or treatment of acute kidney injury. However, clinical studies showing the clinical efficacy of fenoldopam in patients with renal disease are sparse and limited by small sample sizes. Numerous apparently positive reports targeted to surrogate end points, yet severely underpowered, have appeared in the literature. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] A recent trial using fenoldopam to reduce the incidence of death or dialysis at 21 days failed to reach its primary end point, but a post hoc analysis showed promising effects in patients without diabetes. 36 Conversely, 2 previous studies using fenoldopam as a prophylactic agent failed to prevent the development of acute kidney injury. 19, 31 To address this problem, we conducted a systematic review and meta-analysis of data pooled from existing trials to determine the impact of fenoldopam on acute kidney injury, patient mortality, and length of hospital stay in critically ill patients.
METHODS

Search Strategy
Pertinent studies were independently searched in BioMedCentral, CENTRAL, and PubMed (updated October 30, 2005) by 2 trained investigators (G.L., G.G.L.B.-Z.). The full PubMed search strategy, including as key words fenoldopam, kidney disease, and renal failure, was developed according to Biondi-Zoccai et al 37 
Study Selection
References obtained from database and literature searches were independently examined first at the title/abstract level by 2 investigators (G.L., G.G.L.B.-Z.), with divergences resolved by consensus, and then, if potentially pertinent, retrieved as complete articles. The following inclusion criteria were used for potentially relevant studies: (1) random allocation to treatment, (2) comparison of fenoldopam versus control treatment, and (3) performed in surgical or intensive care patients (thus not including patients administered radiocontrast dye). Exclusion criteria were: (1) studies selecting only patients undergoing procedures with angiographic contrast media, (2) nonparallel design (ie, crossover) randomized trials, (3) duplicate publications (in this case, only the article reporting the longest follow-up was abstracted), (4) nonhuman experimental studies, and (5) no outcome data. Two investigators (G.L., G.G.L.B.-Z.) selected studies for the final analysis by independently assessing compliance to selection criteria. Divergences from selection criteria were resolved by consensus (Table 1) .
Data Abstraction and Study Characteristics
Baseline, procedural, and outcome data were abstracted independently by 2 investigators (G.L., T.B.), with divergences resolved by consensus (Table 2) . Specifically, we extracted study design (including patient selection and ran- (Table 3) , additional treatments, definition of new or worsening acute kidney injury (Table 4) , requirements for renal replacement therapy (RRT), and length of follow-up. At least 2 separate attempts at contacting original investigators were made in case of missing data. The primary end point of our analysis is to determine the effect of fenoldopam on the number of patients progressing to acute kidney injury that requires at least 1 episode of RRT. The coprimary end point is the incidence of in-hospital mortality. Secondary end points include the incidence of acute kidney injury and hypotension, peak serum creatinine levels, long-term survival, and the duration of intensive care unit (ICU) and hospital stays.
Internal Validity Assessment
The internal validity of included trials was appraised according to The Cochrane Collaboration methods, ie, judging risk for selection, performance, attrition, and adjudication biases, and expressed as low risk of bias (A), moderate risk of bias (B), high risk of bias (C), or incomplete reporting leading to inability to ascertain the underlying risk of bias (D) . 38 In addition, allocation concealment was explicitly distinguished as adequate (A), unclear (B), inadequate (C), or not used (D; Table 5 ). Two independent reviewers (G.L., G.G.L.B.-Z.) appraised study quality, with divergences resolved by consensus.
Data Analysis and Synthesis
Agreement for study selection and quality appraisal ( Table 5) was assessed with the Cohen statistic. 39 Binary outcomes from individual studies were analyzed according to the Mantel-Haenszel model to compute individual odds ratios (ORs) with pertinent 95% confidence intervals (CI), and a pooled summary effect estimate was calculated by means of a fixed-effects model. 40 Weighted means differences (WMDs) and 95% CI were computed for continuous variables. 38 We assessed the robustness of findings from the primary analysis to the effects of study population and baseline risk of any of the primary outcomes through a series of sensitivity analyses, including a random-effects model, and by withdrawing 1 study at a time.
Statistical heterogeneity and inconsistency were measured by using Cochran Q tests and I 2 , respectively. 41 The risk of small-study bias (including publication bias) was assessed by using visual inspection of funnel plots and computing the Egger test. 42 Statistical significance is set at This study was performed in compliance with The Cochrane Collaboration and the Quality of Reporting of MetaAnalyses (QUOROM) guidelines.
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RESULTS
Database searches, snowballing, and contacts with experts yielded a total of 154 citations (Fig  1) . Excluding 111 nonpertinent titles or abstracts (Table 2) , we retrieved 43 studies in complete form and assessed them according to the selection criteria. A total of 27 studies were further excluded because of their nonexperimental design, including the use of historic controls, or because of duplicate publication. Specifically, we excluded 4 studies because of duplicate publication either explicitly acknowledged or allowed 21, 24, 35 or not. 27 We excluded 11 studies 43-54 because there were no outcome data and additional details could not be obtained from the investigators, 6 crossover trials, 9,15,55-57 4 studies with matched controls, [58] [59] [60] [61] and a large prospective study with propensity score analysis. 62 We finally identified 16 eligible randomized clinical trials, which were included in the final analysis (Table 1) . Agreement for study selection appeared high (Cohen , 0.93; 95% CI, 0.87 to 1.0).
Study Characteristics
The 16 included randomized controlled trials (RCTs) randomly assigned 1,290 patients (622 patients to fenoldopam and 668 patients to placebo or best available treatment, mostly lowdose dopamine; Table 3 ). Five trials were performed in cardiac surgery; 3 trials, in vascular surgery; 2 trials, in liver transplantation; and 1 trial, in renal transplantation, while 5 studies were performed in the ICU in either selected patients with sepsis (2 studies) or the overall ICU population. All except 1 study 17 focused on the renal protective properties of fenoldopam.
Fenoldopam dosage varied across studies, always greater than 0.025 g/kg/min and most often 0.1 g/kg/min, reaching 0.3 g/kg/min in a single study. All except 2 studies 17,28 had a fenoldopam infusion for longer than 12 hours, with 8 studies reporting a 2-day or longer infusion (median duration, 48 hours). There was no standardization of indications for RRT except that patients had to meet standard "clinical criteria." Biochemical definitions for acute kidney injury (ie, serum creatinine concentrations) also were not standardized between trials, and we evaluated the broadest definition of acute kidney injury indicated by each investigator (Table 4) .
Study quality appraisal appeared highly reproducible (Cohen , 0.89; 95% CI, 0.79 to 0.99).
Most studies appeared of suboptimal quality, testified by the common lack of details for the method used for randomized sequence generation and allocation (Table 5 ). Adequate allocation concealment was enforced by only 5 studies. In addition, low risks of selection, performance, attrition, and detection bias could be attributed to only a minority of trials. Finally, only 5 RCTs used a multicenter design, a feature that does not strictly impact on internal validity, but usually increases external validity of a trial.
Quantitative Data Synthesis
Overall analysis showed that in comparison to best medical therapy, fenoldopam was associated with significant reductions in the rates of all major end points. Specifically, fenoldopam use decreased the risk of RRT (34 of 525 patients [6.5%] in the fenoldopam group versus 59 of 569 patients [10.4%] in the control arm; OR, 0.54; 95% CI, 0.34 to 0.84; P for effect ϭ 0.007; P for Fig 4) . In addition to an association with greater inhospital survival, fenoldopam use was associated with a significant reduction in ICU stay (WMD ϭ Ϫ0.61 days; 95% CI, Ϫ0.99 to Ϫ0.23; P for effect ϭ 0.002; P for heterogeneity ϭ 0.82; I 2 ϭ 0%; Fig 5) and shorter time to hospital discharge (WMD ϭ Ϫ1.07 days; 95% CI, Ϫ2.16 to 0.01; P for effect ϭ 0.05; P for heterogeneity ϭ 0.90; I 2 ϭ 0%; Fig 6) Fig 7) . Although nonrenal pleiotropic effects of fenoldopam cannot be ruled out, it is likely that most benefits of fenoldopam were driven by its renoprotective effect, testified by the significant, albeit statistically heterogeneous, lower peak serum creatinine levels (WMD ϭ Ϫ0.20; 95% CI, Ϫ0.24 to Ϫ0.16; P for effect Ͻ 0.001; P for heterogeneity ϭ 0.0008; I 2 ϭ 63.2%; Fig 8) .
Additional Analyses
We assessed the robustness and applicability of our findings through a series of sensitivity analyses, ie, excluding 1 study at a time, switching from fixed-effect to random-effect models, and computing relative risks, as well as risk differences. All subanalyses performed excluding 1 RCT at a time remained in the same direction and magnitude of benefit in support of fenoldopam as the overall analysis for acute kidney injury, RRT, and death. Similarly, randomeffect meta-analyses and relative risk computa- tions confirmed the robustness of the comprehensive and primary analyses. We also appraised the robustness and validity of our findings by exploring the likelihood of small-study bias by means of a funnel plot inspection and an Egger test. We found no major evidence of such bias at either graphical or statistical testing for acute kidney injury, RRT, and death (P at Egger test ϭ 0.391, 0.9, and 0.974, respectively).
DISCUSSION
We performed a meta-analysis of pooled data from several small underpowered studies and showed that fenoldopam is associated with a significantly lower incidence of acute kidney injury and overall mortality in critically ill patients. Although significantly underpowered, most studies included in this analysis showed positive survival trends, consistent with the overall positive results of our meta-analysis.
Despite improvements in intensive care medicine and the delivery of RRT, the mortality associated with acute kidney injury remains unacceptably high. The observation that renal blood flow decreases after the onset of acute kidney injury led to numerous clinical trials investigating the efficacy of parenteral vasodilators in reducing the progression to dialysis-dependent acute kidney injury and improving patient survival. 63, 64 Numerous animal model studies showed that parenteral vasodilators can restore corticomedullary blood flow during periods of ischemia and that early administration of these agents can reduce the burden of necrotic tubules.
63-66 Use of vasodilators in patients with acute kidney injury is based upon the assumption that increasing renal blood flow will reduce progression to dialysis therapy and improve survival. However, previous studies using parenteral vasodilators, including dopamine, atrial natriuretic peptide, and insulin growth factor 1, failed to reduce the incidence of dialysis-dependent acute kidney injury or overall mortality. 5, 6, 67 To date, 3 meta-analyses of controlled clinical trials involving the prophylactic or therapeutic use of "renal-dose" dopamine in patients with acute kidney injury failed to show a protective effect on the development of acute kidney injury or need for RRT. [68] [69] [70] The failure of dopamine to function as a prophylactic agent may be caused by the divergent effects of specific dopamine receptors in the mammalian kidney. For example, activation of dopamine A-1 receptors increases renal blood flow in normal and diseased kidneys, whereas dopamine A-2 receptor activation leads to prolonged vasoconstriction. 71, 72 Although previous studies failed to show a renal protective effect, intravenous administration of dopamine to patients at risk of acute kidney injury does not lead to additional renal injury. 68 This observation allowed us to include RCTs comparing renal-dose dopamine with fenoldopam mesylate.
The failure of previous vasodilators to improve the outcome of patients with acute kidney injury may involve deficiencies in trial design and study end points. For example, previous trials of patients with acute tubular necrosis failed to standardize the initiation of dialysis therapy, thus allowing for the primary end point of many studies to be determined by individual practice patterns. This lack of uniformity has allowed for variability in the primary end point and reduced the ability to show a significant drug effect. Only a single study used in our analysis had predefined criteria indicating when a patient reached a dialytic end point. 73 Moreover, previ- ous trials varied about the timing of drug administration. A delay in drug administration could allow for progression to the later phases of acute kidney injury that are no longer responsive to vasodilator therapy. 74, 75 In addition, variableeffects vasodilator effects on preload, cardiac output, and onset of hypotension also affect results of specific trials.
Fenoldopam mesylate is a selective dopamine A-1 receptor agonist, was shown to decrease systemic vascular resistance in a dose-dependent manner, and is able to augment renal blood flow in patients with normal renal function and chronic renal failure. [8] [9] [10] 73, 76 Recent animal model studies further show that the stimulatory effects of fenoldopam on renal blood flow are proportionately greater in the outer medulla. 77 In contrast to dopamine, intravenous fenoldopam does not increase cardiac output because of its greater specificity for dopaminergic receptors and lack of crossover activation of ␤-adrenergic receptors. 10 Most clinicians use fenoldopam in the belief that improving renal blood flow and oxygen delivery will disrupt the progression toward dialysisdependent acute kidney injury. Between doses of 0.03 and 0.1 g/kg/min, fenoldopam can significantly increase renal blood flow without decreasing systemic vascular resistance. 9, 78 Moreover, infusions as low as 0.03 g/kg/min showed beneficial effects on renal function. 9 Despite the absence of appropriately powered prospective trials, use of fenoldopam in patients with renal dysfunction has become standard practice. Moreover, it has not been established whether improving blood flow in patients with acute kidney injury can reduce the burden of ischemic tubules. 79 A recent meta-analysis 80 reviewed different methods to protect renal function during the perioperative period and concluded that there is no convincing evidence to suggest that pharmacological or other interventions are effective in the treatment of patients with acute kidney injury. However, Zacharias et al 80 included only 2 27,28 of the 16 trials used in our meta-analysis. Moreover, several nonrandomized studies showed that fenoldopam decreased the incidence of contrast nephropathy in patients undergoing coronary stent placement. 81, 82 The only large randomized study examining the efficacy of fenoldopam in preventing contrast nephropathy did not support these findings. 83 These contrasting results illustrate the difficulty of using existing trials to reach a consensus on the role of fenoldopam in patients with acute kidney injury. Because no single prospective study supports a protective effect of fenoldopam on decreasing the incidence of acute kidney injury or need for RRT, we conducted a meta-analysis of 16 studies comparing fenoldopam with placebo or usual care. In the 16 RCTs included in our analysis, fenoldopam infusion rates ranged between 0.025 and 0.3 g/kg/min. In our analysis of 1,290 patients enrolled in 16 randomized trials, use of fenoldopam significantly decreased the risk of acute kidney injury, need for RRT, and hospital mortality Moreover, fenoldopam decreased the duration of ICU and total hospital stays. Remarkably, the incidence of hypotension and/or use of vasoconstrictors did not increase significantly in patients administered fenoldopam. The lack of hypotension associated with fenoldopam in part may explain the beneficial findings of fenoldopam compared with other vasodilators.
The limitations of systematic reviews and meta-analyses are well known and include the level of uniformity among study populations, as well as the primary end points in each study. 84 Particular attention should be drawn to the overall suboptimal quality of the RCTs included because lower quality studies may provide biased effect estimates. However, even after excluding studies with inadequate allocation concealment (Table 5) , fenoldopam was associated significantly with a decrease in risk of acute renal failure (OR, 0.60; 95% CI, 0.42 to 0.86; P for effect ϭ 0.005; P for heterogeneity ϭ 0.42; I 2 ϭ 0%). A particular limitation of our analysis is the lack of uniform clinical indications for the initiation of dialysis therapy. In the majority of randomized trials, initiation of RRT was left to the participating physician. An additional limitation of our study is that several studies had to be eliminated from the analysis because of missing data and failure to contact the primary investigators. Last, there was no independent measure of glomerular filtration rate from which we could correlate infusion with fenoldopam and improvements in renal function. Nonetheless, we strived to comply with the most stringent guidelines of The Cochrane Collaboration and the QUOROM statement. Thus, our results provide the most comprehensive and thorough comparison of fenoldopam versus control treatment in critically ill patients at risk of acute kidney injury that currently exists. In addition, the validity of our results is supported by the lack of evidence of small-study bias or statistical heterogeneity. Only an individual patient-data meta-analysis or a large and adequately powered RCT could provide a sounder and more rigorous appraisal of the clinical role of fenoldopam in this clinical setting.
In conclusion, intravenous infusion of fenoldopam mesylate to patients at risk of acute kidney injury appears to decrease the development of acute tubular necrosis, requirement for RRT, and overall patient mortality. Given the limitations of meta-analysis, our analysis supports the renal protective effects of fenoldopam mesylate. A larger multicenter RCT is needed to confirm these results. 
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